Identifying barriers to hepatitis C virus elimination in the era of direct-acting antivirals

Read full text
Authors: Thomas Talbot, Gillian Farrell, Catherine Murray, Priyanka Mandel, Ciara Houlihan, Fiona Herraghty, Nessa Quinn, Aoife Coffey, Shannyn Sheehan, Miriam Coghlan, Concepta Merry, Colm Kerr
+5 more Niamh Allen, Clíona Ní Cheallaigh, Ciaran Bannan, Liam Townsend, Colm Bergin
Cited by: 1
References: 29

Abstract

OBJECTIVES: Hepatitis C virus (HCV) infection elimination is possible through direct-acting antiviral (DAA) therapy. Retention in care remains challenging. We aimed to identify factors associated with failure to engage in care and achieve sustained virological response (SVR) following DAA therapy. METHODS: We conducted a retrospective review of 11 years of DAA outcomes (2014-2024) at a tertiary referral center in Ireland. Associations with SVR in the total DAA cohort and in those who adhered to the treatment schedule were assessed. Univariate analysis and multivariable logistic regression models identified these factors. RESULTS: There were 881 treatment episodes. The majority were male (77%), with median age of 43. N = 478 attended all scheduled appointments, with SVR of 96% in this cohort. However, the overall confirmed cohort SVR was 86%. Being housed (OR: 1.62, P = 0.03) and having a primary care provider (OR: 1.68, P = 0.02) were associated with achieving SVR. Failure to attend appointments was associated with young age (P < 0.001), homelessness (P < 0.001), prior intravenous drug use (

Fields of Study & Subjects

Hepatitis C virus research Hepatitis B Virus Studies HIV/AIDS drug development and treatment

Publication details

Journal / source
International Journal of Infectious Diseases
Publisher
Elsevier BV
Volume
170
Pages
108849–108849
Publication date
1 June 2026
Language
EN